AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05780437 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% sodium chloride solution
Study NCT05780437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Antiviral agent
Study NCT05780437 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir
Description: Antiviral agent
Study NCT06254079 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video based education
Description: The patients in the experimental group will be shown a video containing information about the operating room environment and care during surgery. The video content includes the following details: the operating room temperature being maintained at 18-24°C; the patient being placed on the operating table by the staff in the presence of an anesthesia technician; the establishment of intravenous access by the anesthesia technician; monitoring of blood pressure, pulse, respiration, and EKG indicators; the insertion of a urinary catheter by the surgical nurse after the patient is anesthetized; post-awakening transfer to the postoperative recovery unit with the anesthesia technician and personnel; reception and monitoring of vital signs, pain assessment, intervention, and observation for a period by a nurse in this unit; and finally, transfer to the General Surgery Service.
Study NCT06546241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Celebrandome
Description: This intervention is based on existing cognitive dissonance body confidence programs for youth such as Amazing Me, Free Being Me, and Body Project. Consistent with these programs, workshops are entirely experiential getting you to discuss appearance ideals and why they are problematic, pressures they experience to conform to appearance ideals, ways to combat pressures, they compare pictures that are normal versus digitally altered and discuss ways this is problematic, they discuss body talk statements they hear all the time and how this promotes appearance ideals, they practice ways to combat body talk statements. They develop positive affirmation statements. In addition and unique to this curriculum, all activities highlight cultural ideals and how youth can receive different messages related to different appearance ideals and they unique stress and pressures this creates.
Study NCT05810246 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-NY104 PET/CT Contrast-enhanced MRI of the brain and contrast-enhanced CT of abdomen and pelvis) 68Ga-NODAGA-LM3 PET/CT (exploratory)
Description: 68Ga-NY104 PET/CT is expected to be completed within 21 days following screening. Participants will be administered a single, intravenous bolus of 68Ga-NY104 (1.8-2.2 MBq per kilogram bodyweight). PET/CT scanning will occur at 45 -75 minutes following injection of 68Ga-NY104.~Conventional imaging should be performed within one month from 68Ga-NY104 PET/CT. It includes contrast-enhanced MRI of brain and contrast-enhanced CT of abdomen and pelvis.~68Ga-NODAGA-LM3 PET/CT is optional in patients with evidence of or in suspicion of pheochromocytoma, paraganglioma, or pancreatic neuroendocrine tumor. They are encouraged to undergo exploratory 68Ga-NODAGA-LM3 PET/CT for better evaluation of neuroendocrine tumors. The decision, however, is up to the participants. 68Ga-NODAGA-LM3 PET/CT should be performed within one month after 68Ga-NY104 PET/CT. The details of 68Ga-NODAGA-LM3 PET/CT are similar to 68Ga-NY104 PET/CT.
Study NCT06356662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: take tenofovir disoproxil fumarate 300mg/d
Study NCT06356662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: take tenofovir disoproxil fumarate 300mg/d
Study NCT05113251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: administered by intravenous infusion
Study NCT04251182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15mg T3D-959
Description: Oral administration once daily in the morning
Study NCT04251182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg T3D-959
Description: Oral administration once daily in the morning
Study NCT04251182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 45 mg T3D-959
Description: Oral administration once daily in the morning
Study NCT04251182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Oral administration once daily in the morning
Study NCT05312567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-101
Description: daily oral tablet administration (b.i.d.)
Study NCT05312567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FP-101
Description: daily oral tablet administration (b.i.d.)
Study NCT05877950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone-based speech therapy
Description: Participants will be instructed to use the speech therapy app for 1 hour per day (5 days for 1 week) over a 4-week period.
Study NCT05877950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based speech therapy
Description: Participants will receive treatment maintaining the same frequency as the intervention group.
Study NCT04356326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 150 mg
Description: Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.
Study NCT04356326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.
Study NCT05113251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: administered by intravenous infusion
Study NCT05113251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: administered by intravenous infusion
Study NCT06491251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Subinguinal microscopic varicocelectomy
Description: Using Leica® Microsystems , Germany. the patient was placed in a supine position after spinal anesthesia administration , The left external inguinal ring was located near the pubic tubercle by palpation, and the incision site was marked below the annulus of the left external ring. A 1.5- to 3-cm oblique incision was made along the skin line. After the tissues were dissected layer by layer, the incision was exposed until the spermatic cord became visible. the spermatic cord was lifted out with Babcock clamp and delivered though the incision and followed by the placement of a nelaton catheter 20 fr below the spermatic cord. The external spermatic vein was located and ligated. The microscopic operation was performed at 10× to 20× magnification.
Study NCT04895410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lemzoparlimab
Description: Intravenous (IV) infusion
Study NCT05104528 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OSYPKA Medical ICONTM Noninvasive CardiometerTM Model C3
Description: Based on its precedent electrical impedance. 4 electrodes are placed on the patient: 2 on the left of the neck and the other 2 on the left lower chest . A low magnitude (2 mA), high frequency (30-100 KHz) alternating electrical current (AC) of constant amplitude is applied through the outer electrodes, and the resulting voltage is received by the inner electrodes. The ratio of the detected voltage to the applied current is the bio-impedance. The principle on which this is based is that during systole, red blood cells flow in a parallel manner, which allows the electrical current to flow easily thereby improving the electrical velocity and decreasing impedance. While during diastole, RBCs are randomly arranged, consequently hindering the electrical current (increased impedance) and decreasing electrical velocimetry. The changes of impedance over time are integrated in a complex algorithm that allows to measure CO and the other parameters.
Study NCT05104528 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fujifilm Sonosite M-Turbo C Ultrasound system
Description: A low-frequency phased array transducer (3.5-5 MHz) will be used to assess the IVC, which lies in the retroperitoneum, to the right of aorta. At or near the junction with the hepatic veins, we will measure the IVC diameter. To properly visualise the IVC, the probe will be inserted in the subxiphoid 4-chamber position with the probe marker oriented vertically to find the right ventricle and atrium. We will see the convergence of the IVC with the right atrium as the probe is progressively aimed towards the spine. We will then follow the IVC inferiorly, to detect the meeting of the hepatic veins with the IVC. M-mode Doppler sonography of the IVC will be used to graphically document the absolute size and dynamic changes in the calibre of the vessel during inspiration and expiration. After the visualisation of the IVC, we will freeze the US screen, and using the caliper function on the US machine, maximum and minimum diameters of the IVC will be documented.
Study NCT05113251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: administered by intravenous infusion
Study NCT05113251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: administered by intravenous infusion
Study NCT05113251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: administered by intravenous infusion
Study NCT05113251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: administered by intravenous infusion
Study NCT05113251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: administered by intravenous infusion
Study NCT05113251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: administered by intravenous infusion
Study NCT05654870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: Oral treatment
Study NCT05654870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching valbenazine
Study NCT04915820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject
Description: intravenous iron carboxymaltose
Study NCT04984226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: Sodium bicarbonate will be dosed at 0.8meq per kilogram of ideal body weight daily (1meq is approximately 84mg). We will use the Devine formula to determine ideal body weight. Investigational Drug Services at both UC Davis and Vanderbilt will compound the sodium bicarbonate. Sodium bicarbonate 650 mg tablets will be over-encapsulated and matching placebo capsules will be prepared. Participants will be limited to a maximum of 9 capsules daily (maximum dose = 5850mg of sodium bicarbonate). Capsules will be dispensed to patients in two separate 8-week allotments. The dose will be rounded to the nearest whole capsule and depending on participant preference may be divided into portions taken twice or thrice daily. Given the high probability of interruption in sodium bicarbonate supply and availability, we may need to change brands of sodium bicarbonate intermittently.
Study NCT04984226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo and filler for for sodium bicarbonate capsules will be comprised of microcrystalline cellulose. Capsule appearance for control and sodium bicarbonate will be the same.
Study NCT04895410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet or IV infusion/injection
Study NCT05256108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 40 mg
Description: Participants will be administered a single dose of 6 capsules containing oxycodone and placebo in a randomized crossover manner
Study NCT05256108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol 600 mg
Description: Participants will be administered a single dose of 6 capsules containing tramadol in a randomized crossover manner
Study NCT05256108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered a single dose of 6 capsules containing placebo in a randomized crossover manner
Study NCT05256108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 600 µg
Description: Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner
Study NCT05256108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 1000 µg
Description: Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner
Study NCT05655676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-NY008
Description: Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY008
Study NCT01055925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: modified polyurethane film dressing (OpSite, Smith&Nephew, London, UK)
Study NCT01055925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel® (ConvaTec, Skillman, NJ, USA), sodium carboxy-methylcellulose hydrocolloid polymer dressing
Study NCT05362396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training with Powerbreath IMT device.
Description: Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks. Each day, each subject perform 5 sets of 10 repetitions, 5 days a week. The endurance of the device increases along the study, initiating with the 50% of their own maximum inspiratory pressure (MIP) during the first week, 2nd week: 55% MIP, 3rd week: 60% MIP, 4th week: 65% MIP, 5th week: 70% MIP, 6th week: 75% MIP, 7th week: 80% MIP and 8th week:80% MIP
Study NCT04895410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: IV infusion
Study NCT04895410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Oral capsule
Study NCT04895410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous (SC) injection
Study NCT05235594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable sensor
Description: The patients will be asked to wear a smart shirt. The shirt is designed with multiple sensors and electrodes fully embedded which engender 6 different measurement flows continuously. The smart t-shirt system is washable, and patients can wash and dry this t-shirt anytime, thus the shirt can be worn repeatedly.
Study NCT04893902 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: medit intra oral scanner
Description: ear scanning with intra oral scanner
Study NCT04893902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medit intra oral scanner
Description: ear scanning with intra oral scanner
Study NCT06575998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: A 4-hour training for PCPs consisting of an onsite training, an e-learning and a webinar on the treatment of insomnia.
Study NCT06575998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pro-active identification
Description: Pro-active identification of patients with clinical insomnia symptoms. Patients receiving care from the participating practices will be asked to fill-out the Insomnia Severity Index (ISI).The ISI is used to identify patients with clinical insomnia symptoms in the general practice. Trained practices will receive feedback on the ISI for half of the patients with clinical symptoms according to the ISI.
Study NCT04968015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine-Venetoclax Association
Description: Consolidation treatment with cytarabine + venetoclax
Study NCT04968015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine-Idarubicin Association
Description: Consolidation treatment with cytarabine + idarubicin
Study NCT06264947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: wavelength: 808nm energy: 18j power: 100mw
Study NCT06264947 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham laser acupuncture
Description: wavelength: 0nm energy: 0j power: 0mw
Study NCT05505123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: induction and maintenance with sevoflurane for deep sedation
Study NCT05505123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: induction and maintenance with propofol for deep sedation
Study NCT05730140 — intervention group
Intervention type: OTHER
Intervention: this study did not involve interventions; it only observational study
Description: this study did not involve interventions. This study is an observational study for elucidating the intraoperative blood pressure changes, artierial stiffness, and whole exome genome
Study NCT05107999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zhizhu Kuanzhong capsules (ZZKZ)
Description: FD patients were treated with ZZKZ and omeprazole for 4 weeks.
Study NCT05107999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxepin Hydrochloride (Doxepin)
Description: FD patients were treated with doxepin and omeprazole for 4 weeks.
Study NCT05901441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: For those in H1 group: they will be administered with15 ug/ml hydromorphone, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone , For those in H3 group: they will be administered with 20 ug/ml hydromorphone
Study NCT05901441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: For those in SF group: they will be administered with 40 ug/ml sufentanil
Study NCT05901441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
Study NCT05901441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
Study NCT05147402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midomafetamine
Description: 100 mg midomafetamine (equivalent to 120 mg midomafetamine HCl).
Study NCT05921292 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Omeza Products Used in Combination
Description: Subjects in this single-arm study will have the targeted wound/ulcer treated with Omeza® combination therapy which includes the use of the following products:~* Omeza® Lidocaine Lavage~* Omeza® Complete Matrix (OCM™)~* Omeza® Skin Protectant At each treatment (on days 0, 7, 14, 21; +/- 3 days each), the patient's intact skin around the wound/ulcer will be prepped with Omeza® Lidocaine Lavage. OCM™ will be applied directly to the wound/ulcer and Omeza® Skin Protectant will be applied to the periwound and surrounding intact skin. Treatments may be repeated during an optional 7 additional weeks (on days 28, 35, 42, 49, 56, 63, and 70; +/- 3 days each). Final assessment will be made at week 12.
Study NCT06314646 — intervention group
Intervention type: PROCEDURE
Intervention: Transanal Transection and Single-Stapled anastomosis (TTSS)
Description: Low anterior rectal resection with Transanal Transection and Single-Stapled anastomosis (TTSS)
Study NCT06314646 — intervention group
Intervention type: PROCEDURE
Intervention: Double-stapled Total Mesorectal Excision (TME)
Description: Low anterior rectal resection with double-stapled Total Mesorectal Excision (TME)
Study NCT05648201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine 100Mg Tab
Description: 1 single dose of 100mg taken orally
Study NCT05648201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir 600Mg Tab
Description: 1 single dose of 1200mg taken orally
Study NCT05648201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy 50/200/25 Tab
Description: 1 single dose of 50/200/25 taken orally
Study NCT06513143 — intervention group
Intervention type: OTHER
Intervention: CT images into virtual 3D model demonstration
Description: The investigators have finished is personalized 3D model translation from CT images into virtual 3D model demonstrated in VR glasses using Synapse.
Study NCT06302153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Progressive Loading Exercises
Description: At start of study, a formal educational session, lasting about 30 minutes will be given by the physiotherapist dealing with the treatment/interventions. Whole treatment plan will be given for six weeks. Pre and post intervention measurements will be taken.
Study NCT05662332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Efsitora Alfa
Description: Administered SC
Study NCT05662332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC
Study NCT05030831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INZ-701
Description: INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).
Study NCT05711485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole blood transfusion
Description: Whole blood is sourced from the Zambia National Blood Transfusion Service.